Skip to main content

Table 1 Socio-demographic and clinical characteristics (n = 1021)

From: Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy

Variable Mild AD (n = 734, 72 %) Moderate AD (n = 287, 28 %) p
Female sex 473/64 % 181/63 % 0.717
APOE ε4 carrier, (n = 999) 493/69 % 186/66 % 0.452
Solitary living at baseline 267/36 % 88/31 % 0.093
Completion rate after 3 years 306/42 % 78/27 % <0.001
Antihypertensives/cardiac therapy 290/40 % 124/43 % 0.288
Antidiabetics 38/5 % 12/4 % 0.629
Asthma medication 28/4 % 16/6 % 0.231
Thyroid therapy 65/9 % 20/7 % 0.378
Lipid-lowering agents 94/13 % 24/8 % 0.050
Oestrogens 52/7 % 17/6 % 0.580
NSAIDs/acetylsalicylic acid 221/30 % 84/29 % 0.820
Antidepressants 183/25 % 74/26 % 0.810
Antipsychotics 26/4 % 21/7 % 0.013
Anxiolytics/sedatives/hypnotics 111/15 % 37/13 % 0.429
Estimated age at onset (years) 72.3 ± 7.1 72.0 ± 7.8 0.544
Estimated duration of AD at baseline (years) 2.9 ± 2.0 3.4 ± 2.3 0.005
Age at first assessment (years) 75.2 ± 6.8 75.3 ± 7.4 0.788
Education (years) 9.6 ± 2.6 9.0 ± 2.2 <0.001
MMSE score at baseline 23.4 ± 2.0 16.4 ± 2.2 <0.001
ADAS-cog score (0–70) at baseline 17.5 ± 6.7 29.3 ± 8.3 <0.001
IADL score at baseline 14.7 ± 5.0 19.1 ± 5.1 <0.001
PSMS score at baseline 7.2 ± 1.9 8.3 ± 2.9 <0.001
Number of concomitant medications at baseline 2.9 ± 2.4 3.0 ± 2.6 0.604
Length in the SATS (months) 24.2 ± 12.9 20.4 ± 13.0 <0.001
Mean dose of ChEI during the follow-up period (mg)    
 Donepezil (n = 518)a 6.9 ± 1.7 (48 %) 6.9 ± 1.8 (57 %) 0.761
 Rivastigmine (n = 212)a 6.2 ± 2.1 (22 %) 6.0 ± 2.2 (17.5 %) 0.536
 Galantamine (n = 291)a 15.3 ± 3.6 (30 %) 14.7 ± 4.0 (25.5 %) 0.198
  1. Data presented as n/% or mean ± standard deviation
  2. aPercentage of patients in each group that received the specific ChEI agent in parentheses (chi-square test; p = 0.035)
  3. AD Alzheimer’s disease, ADAS-cog Alzheimer’s Disease Assessment Scale—cognitive subscale, APOE apolipoprotein E, ChEI cholinesterase inhibitor, IADL Instrumental Activities of Daily Living scale, MMSE Mini-Mental State Examination, NSAID non-steroidal anti-inflammatory drug, PSMS Physical Self-Maintenance Scale, SATS Swedish Alzheimer Treatment Study